Sumitomo Mitsui Trust Group Inc. Trims Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Sumitomo Mitsui Trust Group Inc. trimmed its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 9.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,065,050 shares of the biotechnology company’s stock after selling 210,665 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 0.08% of Arcturus Therapeutics worth $35,044,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. ARK Investment Management LLC increased its holdings in Arcturus Therapeutics by 6.9% in the 3rd quarter. ARK Investment Management LLC now owns 2,101,038 shares of the biotechnology company’s stock worth $48,765,000 after acquiring an additional 136,074 shares in the last quarter. Geode Capital Management LLC boosted its stake in Arcturus Therapeutics by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 551,798 shares of the biotechnology company’s stock worth $12,810,000 after purchasing an additional 5,789 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Arcturus Therapeutics by 1.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 197,622 shares of the biotechnology company’s stock worth $4,587,000 after purchasing an additional 3,224 shares during the period. Royce & Associates LP boosted its stake in Arcturus Therapeutics by 18.3% in the 3rd quarter. Royce & Associates LP now owns 155,803 shares of the biotechnology company’s stock worth $3,616,000 after purchasing an additional 24,085 shares during the period. Finally, Empire Life Investments Inc. bought a new position in Arcturus Therapeutics in the 3rd quarter worth approximately $3,498,000. 94.54% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Stock Performance

NASDAQ ARCT opened at $16.07 on Wednesday. The company has a market capitalization of $435.34 million, a P/E ratio of -7.24 and a beta of 2.62. Arcturus Therapeutics Holdings Inc. has a one year low of $14.30 and a one year high of $45.00. The stock has a 50 day moving average price of $17.12 and a 200-day moving average price of $19.12.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and issued a $63.00 price target on shares of Arcturus Therapeutics in a research note on Monday, January 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. Finally, BTIG Research assumed coverage on Arcturus Therapeutics in a research note on Tuesday, January 28th. They issued a “buy” rating and a $41.00 price target for the company. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $65.00.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.